Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Treasury Shares (2020 - 2025)

Xeris Biopharma Holdings' Treasury Shares history spans 6 years, with the latest figure at $13.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares fell 17.72% year-over-year to $13.5 million, compared with a TTM value of $13.5 million through Dec 2025, down 17.72%, and an annual FY2025 reading of $13.5 million, down 17.72% over the prior year.
  • Treasury Shares for Q4 2025 was $13.5 million at Xeris Biopharma Holdings, down from $13.8 million in the prior quarter.
  • The five-year high for Treasury Shares was $16.4 million in Q4 2024, with the low at $2.1 million in Q3 2021.
  • Average Treasury Shares over 5 years is $11.5 million, with a median of $13.6 million recorded in 2025.
  • Year-over-year, Treasury Shares skyrocketed 120.33% in 2023 and then fell 17.72% in 2025.
  • Tracing XERS's Treasury Shares over 5 years: stood at $2.1 million in 2021, then skyrocketed by 154.76% to $5.3 million in 2022, then skyrocketed by 120.33% to $11.6 million in 2023, then soared by 41.81% to $16.4 million in 2024, then fell by 17.72% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Treasury Shares are $13.5 million (Q4 2025), $13.8 million (Q3 2025), and $14.5 million (Q2 2025).